NCT05427084View on ClinicalTrials.gov

Canagliflozin Targeting Vascular Inflammation

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Diabetes Type 2Coronary Artery Disease

Interventions

DRUG

Canagliflozin

Canagliflozin tablet 300mg PO daily

DRUG

Placebo

Placebo tablet

Trial Locations (1)

K1Y 4W7

RECRUITING

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors

lead

Ottawa Heart Institute Research Corporation

OTHER